Absorption: Bioavailability unknown.
Distribution: Extensively distributed to tissues.
Protein Binding: 97%.
Metabolism/Excretion: Mostly metabolized by the hepatic CYP2C9 isoenzyme; the CYP2C9 enzyme system exhibits genetic polymorphism; poor metabolizers may have significantly ↑ celecoxib concentrations and an ↑ risk of adverse effects; <3% excreted unchanged in urine and feces.
Half-life: 11 hr.
Contraindicated in:
- Hypersensitivity
- Cross-sensitivity may exist with other NSAIDs, including aspirin
- History of allergic-type reactions to sulfonamides
- History of asthma, urticaria, or allergic-type reactions to aspirin or other NSAIDs, including the aspirin triad (asthma, nasal polyps, and severe hypersensitivity reactions to aspirin)
- Advanced renal disease
- Severe hepatic impairment
- Coronary artery bypass graft (CABG) surgery
- OB: Avoid use after 30 wk gestation
Use Cautiously in:
- Cardiovascular disease or risk factors for cardiovascular disease (may ↑ risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, especially with prolonged use or use of higher doses); avoid use in patients with recent MI or HF
- Pre-existing renal disease, heart failure, liver dysfunction, concurrent diuretic, or ACE inhibitor therapy (↑ risk of renal impairment)
- History of peptic ulcer disease or GI bleeding, long duration of NSAID use, smoking, alcohol use, advanced liver disease, coagulopathy, and poor general health (↑ risk of GI bleeding)
- Hypertension or fluid retention
- Renal impairment (may precipitate acute renal failure)
- Serious dehydration (correct deficits before administering)
- Patients who are known or suspected to be poor CYP2C9 metabolizers (↓ initial dose by 50%; in patients with juvenile rheumatoid arthritis, use alternative treatment)
- Pre-existing asthma
- OB: Use at or after 20 wk gestation may cause fetal or neonatal renal impairment; if treatment is necessary between 20 wk and 30 wk gestation, limit use to the lowest effective dose and shortest duration possible
- Pedi: Safety not established in children <2 yr or for longer than 6 mo
- Geri: ↑risk of GI bleeding in older adults.
Exercise Extreme Caution in:
- History of peptic ulcer disease or GI bleeding.
CV: HF, MYOCARDIAL INFARCTION, STROKE, THROMBOSIS, edema, hypertension.
Derm: DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), EXFOLIATIVE DERMATITIS, STEVENS-JOHNSON SYNDROME (SJS), TOXIC EPIDERMAL NECROLYSIS (TEN), rash.
F and E: hyperkalemia.
GI: GI BLEEDING, abdominal pain, diarrhea, dyspepsia, flatulence, nausea.
Neuro: dizziness, headache, insomnia.
Osteoarthritis
- PO (Adults): 200 mg once daily or 100 mg twice daily. CYP2C9 poor metabolizers — ↓dose by 50%.
Hepatic Impairment
- PO (Adults): Moderate hepatic impairment (Child-Pugh Class B) — ↓dose by 50%.
Rheumatoid Arthritis
- PO (Adults): 100–200 mg twice daily (capsules). CYP2C9 poor metabolizers — ↓dose by 50%.
Hepatic Impairment
- PO (Adults): Moderate hepatic impairment (Child-Pugh Class B) — ↓dose by 50%.
Ankylosing Spondylitis
- PO (Adults): 200 mg once daily (capsules) or 100 mg twice daily (capsules); may ↑ dose after 6 wk to 400 mg/day. CYP2C9 poor metabolizers — ↓dose by 50%.
Hepatic Impairment
- PO (Adults): Moderate hepatic impairment (Child-Pugh Class B) — ↓dose by 50%.
Juvenile Rheumatoid Arthritis
- PO (Children
2 yr, 10–25 kg): 50 mg twice daily (capsules). - PO (Children 2 yr, 25 kg): 100 mg twice daily (capsules).
Hepatic Impairment
- PO (Children 2 yr): Moderate hepatic impairment (Child-Pugh Class B) — ↓dose by 50%.
Acute Pain or Primary Dysmenorrhea
- PO (Adults): 400 mg initially, then a 200-mg dose if needed on the first day; then 200 mg twice daily as needed (capsules). CYP2C9 poor metabolizers — ↓dose by 50%.
Hepatic Impairment
- PO (Adults): Moderate hepatic impairment (Child-Pugh Class B) — ↓dose by 50%.
Therapeutic Classification: antirheumatics
Pharmacologic Classification: cox 2 inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs)
